1. Murthy V, Aggarwal R, Koo PJ. The emerging role of next-generation imaging in prostate cancer. Curr Oncol Rep. 2022;24(1):33–42.
2. Werner RA, Derlin T, Lapa C, et al. 18F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging. Theranostics. 2020;10(1):1–16.
3. Blue Earth Diagnostics. POSLUMA (flotufolastat F 18) injection, for intravenous use. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216023s000lbl.pdf. Accessed 26 Jun 2023.
4. Blue Earth Diagnostics. U.S. FDA approves Blue Earth Diagnostics’ POSLUMA® (flotufolastat F 18) injection, first radiohybrid PSMA-targeted PET imaging agent for prostate cancer [media release]. 30 May 2023. https://www.businesswire.com/news/home/20230530005180/en/U.S.-FDA-Approves-Blue-Earth-Diagnostics%E2%80%99-POSLUMA%C2%AE-Flotufolastat-F-18-Injection-First-Radiohybrid-PSMA-targeted-PET-Imaging-Agent-for-Prostate-Cancer.
5. Bracco Imaging. Bracco Imaging launches new subsidiary, Blue Earth Therapeutics, to advance development of next generation therapeutic radiopharmaceutical technology [media release]. 1 Mar 2022. http://www.braccoimaging.com.